Skip to main content

Market Overview

Biofrontera To Sell Photodynamic Therapy For Skin Diseases In Poland Via Supply Pact With Medac

Share:
Biofrontera To Sell Photodynamic Therapy For Skin Diseases In Poland Via Supply Pact With Medac
  • Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG (NASDAQ: BFRA) and Medac Gesellschaft für klinische Spezialpräparate mbH have signed an exclusive license and supply agreement for the marketing of both Ameluz and BF-RhodoLED in Poland. 
  • The agreement has a term of 5 years commencing with the start of sales in Poland.
  • Under the terms of the agreement, Medac will make an immediate one-time upfront payment of €50,000, plus an additional one-time payment of €150,000 after the drug's reimbursement eligibility in Poland. 
  • In 2011, Ameluz was approved for photodynamic therapy (PDT) of mild to moderate actinic keratoses, field cancerization, and superficial and nodular basal cell carcinomas. 
  • Ameluz is approved for use in conventional PDT with red-light lamp BF-RhodoLED as well as for daylight PDT.
  • Price Action: BFRA shares are up 1.7% at $6.55 during the premarket session on the last check Friday.
 

Related Articles (BFRA)

View Comments and Join the Discussion!

Posted-In: BriefsBiotech News Health Care Contracts Asset Sales General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com